Case report
A 13-month-old female infant has experienced recurrent seizures since she was 18 days old. Most of the seizures presented as generalized tonic-clonic seizure, which lasted for about several minutes per time and occurred 3-4 times per day. The patient was born at term after an unremarkable pregnancy. There was no family history of epilepsy or other neurologic disorders. On examination, we found that her developmental delay was significant. She still can not sit by herself. Left hemiparesis with grade 3 muscle strength was found. Muscle tone over whole body was decreased. No facial deformity, congenital heart defects, microcephaly was found. The ambulatory EEG revealed interictal epileptiform discharges on the region of right frontal lobe (F4 and C4) (Fig. 1A) . Neuroimaging revealed right frontal, parietal and temporal pachygyria, which was 4b (anterior-predominant pachygyria) in the Grading system for lissencephaly (Fig. 1B) [3] . Although three antiepileptic drugs of levetiracetam, valproic acid and topiramate were prescribed, no improvement of the epilepsy was observed. To identify the cause of disease, genetic test was performed using a panel containing 480 epilepsy-related genes based on Next-generation sequencing (List of the genes in supplemental data). A heterozygous frameshift mutation c.4662_4663delAG (p.D1556*) in DEPDC5 gene (reference transcript, NM_001242896) was detected in the patient. This mutation was not recorded in databases including dbSNP 146, 1000 Genomes, the NHLBI Exome Sequencing Project and the Exome Aggregation Consortium database. This mutation was further confirmed by Sanger sequencing and was not detected in either of the healthy parents (Fig. 1C) . The MutationTaster predicted this mutation as disease causing. Other lissencephaly/pachygyriarelated genes like PAFAH1B1, RELN, TUBA1A, NDE1, LAMB1, CDK5, DCX, ARX, TUBB2B, ACTB and VLDLR were all included in the panel and no candidate mutation in these genes was detected [3] . Although some other lissencephaly/pachygyria-related genes like KATNB1, ACTG1, TUBG1, WRD62 were not included in the panel, differences in clinical and neuroimaging features between our patient and patients with mutations in those genes make them less likely to be causative genes in this case [3] .
Discussion
Pachygyria is a kind of lissencephaly, in whose severe type the cortex lacks surface folds (agyria), while milder manifestations include abnormally broad folds (pachygyria) or a heterotopic layer of gray matter embedded in the white matter below the cortex (subcortical band heterotopia, SBH) [3] . The pathogenesis of lissencephaly is associated with abnormal cell migration, in which slow or arrested migration leads to a thickened cortex with reduced folding (pachygyria or agyria) or the stranded neurons of SBH [3] . Lissencephaly is a kind of malformations of cortical development and most patients with lissencephaly present intractable epilepsy and significant developmental delay. About 15 genes associated with lissencephaly have been reported [3] .
DEPDC5 is an upstream negative regulator of mammalian target of rapamycin (mTOR) complex 1 and mutations in DEPDC5 gene cause a wide phenotypic spectrum. Baulac et al. reported that mutations in DEPDC5 may cause epilepsy associated with focal cortical dysplasia, which is another kind of malformations of cortical development [2] . This association is consistent with the result of a miRNA expression analysis in cortical dysplasia, which indicated that the mTOR signaling pathway is the most significantly associated with cortical dysplasia [4] . Interestingly, in the same study, Lee et al. noted that the pathway of lissencephaly gene in neuronal migration and development was also associated with cortical dysplasia [4] . These reports indicated that lissencephaly and cortical dysplasia may share similar pathogenesis on genetic molecular level. Our report offered further evidence for the connection between lissencephaly and cortical dysplasia and also expanded the phenotypic spectrum of DEPDC5. Some limitations exist in our report. First, not all lissencephaly/pachygyria-related genes could be excluded as the possible causative gene by Nextgeneration sequencing, although the clinical and neuroimaging features in our patient were different from those associated with some lissencephaly/pachygyria-related genes not excluded. Second, the patient was sporadic and the mutation was de novo. There was no other patient to reconfirm this finding. Third, the position of the mutation À c.4662_4663delAG (p.D1556*) was very close to the stop codon and it only slightly truncated protein (the last 39 amino acids). It was never reported a truncated mutation more close to the stop codon before. Further functional studies about this mutation would be helpful to confirm the potential pathogenicity of this mutation. We propose that more studies of DEPDC5 gene in patients with lissencephaly should be performed. The underlying relationship among lissencephaly, DEPDC5 gene, cortical dysplasia and mTOR signaling pathway is also worth of further research, which may reveal more pathogenesis of malformations of cortical development.
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